Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.3%
- Check38 days agoChange DetectedThe status of the project has been updated to 'Unknown' and the revision number has changed from v2.14.2 to v2.14.3. Additionally, the previous status of 'Active, not recruiting' has been removed.SummaryDifference3%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.